Detalhe da pesquisa
1.
Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission.
Blood
; 143(5): 417-421, 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37879077
2.
Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemia.
Blood
; 141(9): 996-1006, 2023 03 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36108341
3.
Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia.
Blood
; 142(19): 1647-1657, 2023 11 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37441846
4.
North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need.
Blood
; 141(6): 567-578, 2023 02 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36399715
5.
Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia.
Cancer
; 2024 Apr 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38591430
6.
Characteristics and outcomes of acute myeloid leukaemia patients with baseline CD7 expression.
Br J Haematol
; 2024 Apr 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38603594
7.
Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine.
Blood
; 140(15): 1674-1685, 2022 10 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-35960871
8.
The role of allogeneic transplant for adult Ph+ ALL in CR1 with complete molecular remission: a retrospective analysis.
Blood
; 140(20): 2101-2112, 2022 11 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-35877996
9.
TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia.
Blood
; 140(1): 58-72, 2022 07 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35390143
10.
Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status.
Blood
; 139(14): 2145-2155, 2022 04 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34995344
11.
Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms.
Blood
; 140(16): 1753-1763, 2022 10 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-35512188
12.
Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia.
Blood
; 139(12): 1908-1919, 2022 03 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34914826
13.
Molecular responses in decitabine- and decitabine/venetoclax-treated patients with acute myeloid leukemia and myelodysplastic syndromes.
Haematologica
; 2024 Apr 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38618679
14.
Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups.
Am J Hematol
; 99(4): 792-796, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38361282
15.
A retrospective study of cladribine and low-dose cytarabine-based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia.
Cancer
; 129(4): 560-568, 2023 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36458426
16.
Prediction of survival with lower intensity therapy among older patients with acute myeloid leukemia.
Cancer
; 129(7): 1017-1029, 2023 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36715486
17.
Association between bariatric surgery and outcomes in chronic myeloid leukemia.
Cancer
; 129(12): 1866-1872, 2023 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36882573
18.
Survival outcomes in patients with acute myeloid leukaemia who received subsequent therapy for relapse in QUAZAR AML-001.
Br J Haematol
; 2023 Nov 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37952982
19.
Phase 1/2 study of CPX-351 for patients with Int-2 or high risk International Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic leukaemia after failure to hypomethylating agents.
Br J Haematol
; 2023 Nov 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37946611
20.
Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemia.
Br J Haematol
; 203(4): 581-592, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37608562